Part,  Chapter, Paragraph

  1    I,     2. 10.  3(7) |                     Freeman C, Soete L, Efendioglu U (1995): Diffusion
  2    I,     2. 11        |                     Freeman C, Soete L, Efendioglu U (1995): Diffusion
  3    I,     3.  4        |                     Prioux F (1993): L’infecondité en Europe, in
  4    I,     3.  4        |              Europe, in A. Blum e J. L. Rallu (eds) Démographie
  5    I,     3.  4        |          Paris, 231-251.~ ~Toulemon, L (1995): The Place of Children
  6   II,     5.  2.  4    |      existing definitions ( 5.2 mmol/l, 6.2, 6.5 or 7.8) and difficulties
  7   II,     5.  2.  4    |            total cholesterol in mmol/l and prevalence of hypercholesterolemia
  8   II,     5.  2.  4    |              total cholesterol (mmol/L) and BMI (Kg/m2 ) men and
  9   II,     5.  2.  6    |             A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby
 10   II,     5.  2.  7    |       S35-S40.~Giampaoli S, Palmieri L, Panico S et al (2006):
 11   II,     5.  2.  7    |          Lancet 335:675-87.~Palmieri L, Donfrancesco C, Giampaoli
 12   II,     5.  2.  7    |         Panico S, Vanuzzo D, Pilotto L, Cesana G, Ferrario M, Chiodini
 13   II,     5.  2.  7    |              570.~Panico S, Palmieri L, Donfrancesco C, Vanuzzo
 14   II,     5.  2.  7    |              M, Mattiello A, Pilotto L, Sega R, Giampaoli S, Stamler
 15   II,     5.  3.  9    |               Allemani C, Ciccolallo L, Santaquilani M, Berrino
 16   II,     5.  3.  9    |          Gatta G, Micheli A, Mangone L, Kunkler I, and the EUROCARE-4
 17   II,     5.  4.  1    |             hyperglycaemia 11.1 mmol/l (200mg/dl) in a random sample
 18   II,     5.  4.  1    |       fasting plasma sample 7.0 mmol/l (126 mg/dl) and /or a postprandial
 19   II,     5.  4.  1    |         postprandial value 11.1 mmol/l. (Report WHO/IDF 2006).
 20   II,     5.  4.  2    |             total cholesterol>5 mmol/l~14~Percent of diabetic subjects
 21   II,     5.  4.  2    |             months with LDL>2.6 mmol/l (>3 mmol/l)~13~Percent of
 22   II,     5.  4.  2    |              LDL>2.6 mmol/l (>3 mmol/l)~13~Percent of diabetic
 23   II,     5.  4.  2    |            months with HDL<1.15 mmol/l (<1.0 mmol/l)~11~Percent
 24   II,     5.  4.  2    |           HDL<1.15 mmol/l (<1.0 mmol/l)~11~Percent of diabetic
 25   II,     5.  4.  2    |              triglycerides >2.3 mmol/l (>2.0 mmol/l)~12~Percent
 26   II,     5.  4.  2    | triglycerides >2.3 mmol/l (>2.0 mmol/l)~12~Percent of diabetic
 27   II,     5.  4.  2    |             serum creatinine 400 mol/l~9~Annual incidence of amputations
 28   II,     5.  4.  2    |              equal or above 6.1 mmol/l and below 7.0 mmol/l (fasting
 29   II,     5.  4.  2    |            mmol/l and below 7.0 mmol/l (fasting plasma glucose
 30   II,     5.  4.  2    |              plasma glucose 6,1 mmol/l and <7,0 mmol/l).~Measurement
 31   II,     5.  4.  2    |             6,1 mmol/l and <7,0 mmol/l).~Measurement of glycated
 32   II,     5.  4.  2    |             cholesterol level>5 mmol/l is an important indicator
 33   II,     5.  4.  2    |             cholesterol above 5 mmol/l.~Measurement of LDL cholesterol
 34   II,     5.  4.  2    |          cholesterol level >2.6 mmol/l is an important indicator
 35   II,     5.  4.  2    |    presenting a value above 2.6 mmol/l.~Measurement of HDL cholesterol
 36   II,     5.  4.  2    |          cholesterol level <1.0 mmol/l for men and <1.25 mmol/l
 37   II,     5.  4.  2    |             l for men and <1.25 mmol/l for women is measured as
 38   II,     5.  4.  2    |              0 for men and 1.25 mmol/l for women.~Measurement of
 39   II,     5.  4.  2    |        Triglycerides level >2.3 mmol/l is an important indicator
 40   II,     5.  4.  2    |           cholesterol above 2.3 mmol/l.~Microalbuminuria should
 41   II,     5.  4.  2    |           above or equal to 400 umol/l (WHO).~The annual incidence
 42   II,     5.  4.  3    |             cholesterol level>5 mmol/l. In EUCID databases this
 43   II,     5.  4.  3    |          cholesterol level >2.6 mmol/l. Crude percentages published
 44   II,     5.  4.  3    |          cholesterol level <1.0 mmol/l for men and <1.25 mmol/l
 45   II,     5.  4.  3    |             l for men and <1.25 mmol/l for women. Crude percentages
 46   II,     5.  4.  3    |        Triglycerides level >2.3 mmol/l. In EUCID databases this
 47   II,     5.  4.  8    |          Armesto SG, Lapetra ML, Wei L, Kelley E and the Members
 48   II,     5.  4.  8    |             2000), Marke LA, Nystrom L, Wall S, Ostman J., Excess
 49   II,     5.  5.Int(18)|             M, Tsuboi K, Dennerstein L.(2004): Prevalence of eating
 50   II,     5.  5.  3    |             437-52.~Carney CP, Jones L, Woolson RF (2006): Medical
 51   II,     5.  5.  3    |            Holt RI, Bushe C, Citrome L (2005): Diabetes and schizophrenia
 52   II,     5.  5.  3    |             T, Suvisaari J, Peltonen L, Lonnqvist J (1997): Schizophrenia
 53   II,     5.  5.  3    |        Research Team (PORT) Project. L Amer Acad Psychoanalysis
 54   II,     5.  5.  3    |             T, Mackeprang T, Hansson L, Werdelin G, Karlsson H,
 55   II,     5.  5.  3    |           Osservatorio Regionale per lEpilessia, 1996). On this
 56   II,     5.  5.  3    |             Behav 1:S9-S14.~Forsgren L, Bucht G, Erksson S, Bergmark
 57   II,     5.  5.  3    |         Bucht G, Erksson S, Bergmark L (1996): Incidence and clinical
 58   II,     5.  5.  3    |       Epilepsia 37:224-229.~Forsgren L (2004): Epidemiology and
 59   II,     5.  5.  3    |          Science; p. 21-42.~Forsgren L, Beghi E, Oun A, Sillanpaa
 60   II,     5.  5.  3    |            1409.~Lindsten H, Nystrom L, Forsgren L (2000): Mortality
 61   II,     5.  5.  3    |      Lindsten H, Nystrom L, Forsgren L (2000): Mortality risk in
 62   II,     5.  5.  3    |             H, Stenlund, H, Forsgren L (2001): Remission of seizures
 63   II,     5.  5.  3    |          Psychiatry 69:13-17.~Nashef L, Fish DR, Garner S, et al (
 64   II,     5.  5.  3    |       Epilepsia 36:1187-1194.~Nashef L, Walker F, Allen P, et al (
 65   II,     5.  5.  3    |       Psychiatry 60:297-300.~Nilsson L, Tomson T, Farahmand BY,
 66   II,     5.  5.  3    |      Epilepsia 38:1062-1068.~Nilsson L, Ahlbom A, Farahmand BY,
 67   II,     5.  5.  3    |        Epilepsia 43:644-651.~Nilsson L, Ahlbom A, Farahmand BY,
 68   II,     5.  5.  3    |           Osservatorio Regionale per lEpilessia (1996): ILAE classification
 69   II,     5.  5.  3    |         Pazzaglia P, Frank-Pazzaglia L (1976): Record in grade
 70   II,     5.  5.  3    |          1007.~Sidenvall R, Forsgren L, Blomquist HK, Heijbel J (
 71   II,     5.  5.  3    |            65.~Sidenvall R, Forsgren L, Heijbel J (1996): Prevalence
 72   II,     5.  5.  3    |              45: 667-672.~Vignatelli L, Tonon C, DAlessandro R,
 73   II,     5.  5.  3    |            LICE~Lega Italiana contro lEpilessia~NICE~National
 74   II,     5.  5.  3    |              234.~Becus T, Popoviciu L (1994): Epidemiologic survey
 75   II,     5.  5.  3    |        Benito-Léon J, Martín E, Vela L et al (1998): Multiple sclerosis
 76   II,     5.  5.  3    |              D, Kmetska K, Jordanova L, Topalov N (1997): Prevalence
 77   II,     5.  5.  3    |              CM, Paty DW, Scheinberg L, et al (1983): New diagnostic
 78   II,     5.  5.  3    |        Sobocki P, Pugliatti M, Lauer L, Kobelt G (2007): Estimation
 79   II,     5.  5.  3    |             28.~Sundström P, Nyström L, Forsgren L (2001): Prevalence
 80   II,     5.  5.  3    |     Sundström P, Nyström L, Forsgren L (2001): Prevalence of multiple
 81   II,     5.  5.  3    |            218.~Sundström P, Nyström L, Forsgren L (2003): Incidence (
 82   II,     5.  5.  3    |     Sundström P, Nyström L, Forsgren L (2003): Incidence (1988-
 83   II,     5.  5.  3    |              Svenningsson A, Nyström L, et al (2004): Clinical
 84   II,     5.  5.  3    |            multiple sclerosis in the L’Aquila district, central
 85   II,     5.  5.  3    |            Geneve.~Zivadinov R, Iona L, Monti-Bragadin L, et al (
 86   II,     5.  5.  3    |               Iona L, Monti-Bragadin L, et al (2003): The use of
 87   II,     5.  5.  3    |               Grigoletto F, Amaducci L, Inzitari D (2000): Parkinson’
 88   II,     5.  5.  3    |               Dartigues JF, Amaducci L, Lopez-Pousa S, Manubens-Bertran
 89   II,     5.  5.  3    |          Disord. 14:28-37.~ ~Findley L, Aujla M, Bain PG, Baker
 90   II,     5.  5.  3    |        Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992): The accuracy
 91   II,     5.  5.  3    |          Rosati G, Granieri E, Pinna L, Devoto MC (1979): The frequency
 92   II,     5.  5.  3    |          Rosati G, Granieri E, Pinna L, Aiello I, Tola R, De Bastiani
 93   II,     5.  6.  6    |   Ferraccioli G, Hazes JM, Klareskog L, Machold K, Martin-Mola
 94   II,     5.  6.  6    |          Thiesce A, Listrat V, Jacob L, Nakache JP, Gabriel KR,
 95   II,     5.  6.  6    |              64(10):1456-61~Jacobson L. and Lindgren B (1996):
 96   II,     5.  6.  6    |       M101-M107~Meerding WJ, Bonneux L, Polder JJ, Koopmanschap
 97   II,     5.  7.  7    |              Diez Roux AV, Chambless L, Merkin SS, Arnett D, Eigenbrodt
 98   II,     5.  8.  7    |        Respir J 23: 402-406.~ ~Bilde L, Rud Svenning A, Dollerup
 99   II,     5.  8.  7    |              E, Bonnefoy X, Carrozzi L, Viegi G, Charpin D, Annesi-Maesano
100   II,     5.  8.  7    |         Corsico A, Zoia MC, Carrozzi L, Cazzoletti L, Beccaria
101   II,     5.  8.  7    |               Carrozzi L, Cazzoletti L, Beccaria M, Marinoni A,
102   II,     5.  8.  7    |            LM, Romagnoli M, Corbetta L, Casoni G, Busljetic K,
103   II,     5.  8.  7    |       Jimenez-Ruiz CA, Fernandez-Fau L, Viejo JL, Miravitlles M. (
104   II,     5.  8.  7    |            1504.~ ~Murtagh E, Heaney L, Gingles J, Shepherd R,
105   II,     5.  8.  7    |               608-14~ ~ ~Schirnhofer L, Lamprecht B, Vollmer WM,
106   II,     5.  8.  7    |              F, Baldacci S, Carrozzi L, Giuntini C (2000): Prevalence
107   II,     5.  8.  7    |              S, Soriano JB, Carrozzi L (2004): The proportionalVenn
108   II,     5.  9.  4    |              to pet ownership (Fasce L, 2005), but may also be
109   II,     5.  9.  7    |           2002; 20:1071-1079~ ~Fasce L, Tosca MA, Silvestri M,
110   II,     5.  9.  7    |             Figures, ERJ~ ~Mantovani L G, Bettoncelli G, Cricelli
111   II,     5. 10.  7    |        Cornelisse-Vermaat JR, Frewer L, Mills C, AEJ Dubois (2007):
112   II,     5. 10.  7    |               Hourihane JO'B, Frewer L, Knibb RC, Oude Elberink
113   II,     5. 10.  7    |        Journal of the European Union L 109, 6.5.2000, pp. 2942.~htt ~ ~
114   II,     5. 10.  7    |        Journal of the European Union L 308, 25.11.2003, pp. 15–
115   II,     5. 10.  7    |        Journal of the European Union L 75, 22.03.2005, pp. 3334.~htt ~ ~
116   II,     5. 10.  7    |        Journal of the European Union L 310, 28.11.2007, pp. 11–
117   II,     5. 10.  7    |            Koch P, Crevel RW, Frewer L (2004): Information provision
118   II,     5. 10.  7    |            Burney P, Beyer K, Frewer L, Madsen C, Botjes E, Crevel
119   II,     5. 10.  7    |              C, Gislason D, Zuidmeer L, Sodergren E, Sigurdardottir
120   II,     5. 10.  7    |     Fitzpatrick J, Mills C, Privalle L, Vieths S (2007): Evaluating
121   II,     5. 11.  3    |          1980s (B Larsson-Stymne and L Widström, 1985), while in
122   II,     5. 11.  3    |            to be roughly around 30% (L Dotterud and E Falk, 1994).
123   II,     5. 11.  3    |         during the 19851995 period (L Mattila et al. 2001).~ ~
124   II,     5. 11.  3    |              before 20 years of age (L Dotterud and E Falk, 1994).
125   II,     5. 11.  3    |         cobalt (B Larsson-Stymne and L Widström, 1985). Evidence
126   II,     5. 11.  3    |         Environment, 2007;388:24-34.~L Dotterud, E Falk, Metal
127   II,     5. 11.  3    |           379385.~B Larsson-Stymne, L Widstrom, Ear piercing–a
128   II,     5. 11.  3    |           Dermatitis, 2005;52:2935.~L Matt o, Prevalence of nickel
129   II,     5. 11.  7    |             2001.~ ~Fouere S, Adjadj L, Pawin H (2005): How patients
130   II,     5. 11.  7    |           Larsson-Stymne B, Widstrom L (1985): Ear piercing – a
131   II,     5. 11.  7    |           Levi F, Te VC, Randimbison L et al (2001): Trends in
132   II,     5. 11.  7    |       Verboom P, Hakkaart-van Roijen L, et al (2002): The cost
133   II,     5. 11.  7    |        Svensson A, Diepgen Th, Naldi L, Coenraads PJ, Elsner P,
134   II,     5. 12.  7    |             Forte P,~Pisani A, Soldo L, Sarrecchia B, et al (1989):
135   II,     5. 12.  7    |           227.~ ~Shepard CW, Finelli L, Alter MJ (2005): Global
136   II,     7.  7        |      Vincenten J, Brussoni M, Towner L (2006): Child Safety Good
137   II,     7.  7        |                 Racioppi F, Eriksson L, Tingvall C, Villaveces
138   II,     8.  2.  1    |             C. Finlayson, J., Allan, L., Martin, G. and Robinson,
139   II,     8.  2.  1    |            Verdugo, M-A, Wehmeyer, M.L. and Yeager, M.H. (2007).
140   II,     8.  2.  1    |        Määttä, T., Salvador-Carulla, L., Garrido-Cumbrera, M.,
141   II,     8.  2.  1    |          Jørgensen, F., & OFarrell, L., (2005). Brief Research
142   II,     8.  2.  2    |                 Gilbert CE, Anderton L, Dandona L, Foster A. (1999):
143   II,     8.  2.  2    |              CE, Anderton L, Dandona L, Foster A. (1999): Prevalence
144   II,     8.  2.  2    |       Cesareo M, Corsi A and Cerulli L. (2005): Incidence of visual
145   II,     9.  1.  1    |             HW, Graubard BI, Isotalo L (1993): Effect of age, parity,
146   II,     9.  1.  1    |             Kramer MS, Yang H, Morin L, Fretts RC (2000): Determinants
147   II,     9.  1.  1    |           843-9.~ ~Kramer MS, Seguin L, Lydon J, Goulet L (2000b):
148   II,     9.  1.  1    |            Seguin L, Lydon J, Goulet L (2000b): Socio-economic
149   II,     9.  1.  1    |            en Europe: comparaison de l'experience de 9 services
150   II,     9.  1.  1    |       Bakoula C, Hemminki E, Knudsen L, Levasseur M, Schenker J,
151   II,     9.  1.  1    |               Van Reempts P, Gortner L, Milligan D, Cuttini M,
152   II,     9.  1.  2    |             7. References~ ~Abramsky L, Dolk H and a EUROCAT Folic
153   II,     9.  1.  2    |      Portillo I, Addor M-C, Abramsky L, Ritvanen A, Robert-Gnansia
154   II,     9.  1.  2    |              402. ~Busby A, Abramsky L, Dolk H, Armstrong B and
155   II,     9.  1.  2    |         Fevotte J, Kiel G, Mandereau L, for the Occupational Exposure
156   II,     9.  1.  2    |          Bakker M, Gener B, Abramsky L, Addor M-C and Queisser-Luft
157   II,     9.  1.  2    |            Dolk H, Stone D, Abramsky L, Alberman E, Scott JES (
158   II,     9.  2.  7    |            health (2003-2008), OJ No L 271, 9 October 2002.~ ~European
159   II,     9.  2.  7    |              health (2008-13), OJ No L 301, 20 November 2007.~ ~
160   II,     9.  3.  1    |              300 ng/dl (or 10.4 nmol/L) of total testosterone as
161   II,     9.  3.  1    |              dl (50 pg/ml)(0.17 nmol/L).~ ~In a joint statement
162   II,     9.  3.  1    |             off of 230 ng/dL (8 nmol/L) of total testosterone is
163   II,     9.  3.  1    |              is > 346 ng/dL (12 nmol/L) ART is not necessary, while
164   II,     9.  3.  1    |              respectively: <180 pmol/L (52 pg/ml), between 180
165   II,     9.  3.  1    |             between 180 and 250 pmol/L (72 pg/ml) and > 250 pmol/
166   II,     9.  3.  1    |             72 pg/ml) and > 250 pmol/L (52 pg/ml).~ ~A complete
167   II,     9.  3.  1    |          D.R. Fourcade R. Kiemeney , L, Lee C. and the UrEpik Study
168   II,     9.  3.  1    |      Brownhill S, Wilhelm K, Barclay L & Schmied V (2005): 'Big
169   II,     9.  3.  1    |           sti.2004.009415~ ~Forsgren L, Beghi E, Õun A, Sillanpää
170   II,     9.  3.  1    |             M, Tsuboi K, Dennerstein L (2004); Prevalence of eating
171   II,     9.  3.  2    |             HW, Graubard BI, Isotalo L (1993): Effect of age, parity,
172   II,     9.  3.  2    |             Kramer MS, Yang H, Morin L, Fretts RC (2000): Determinants
173   II,     9.  3.  2    |              22.~ ~Kramer MS, Seguin L, Lydon J, Goulet L (2000):
174   II,     9.  3.  2    |            Seguin L, Lydon J, Goulet L (2000): Socio-economic disparities
175   II,     9.  3.  2    |            en Europe: comparaison de l'experience de 9 services
176   II,     9.  3.  2    |           332(7547):937-9.~ ~Le Fort L (1866) : Des maternités
177   II,     9.  3.  2    |            1866) : Des maternités de l'Europe. Paris: Masson, 1866.~ ~
178   II,     9.  3.  2    |          Marret S, Ancel PY, Marpeau L, Marchand L, Pierrat V,
179   II,     9.  3.  2    |              PY, Marpeau L, Marchand L, Pierrat V, Larroque B,
180   II,     9.  3.  2    |            Petersburg: Imprimerie de l'Academie Imperiale des Sciences,
181   II,     9.  3.  2    |       Bakoula C, Hemminki E, Knudsen L, Levasseur M, Schenker J,
182   II,     9.  3.  2    |               Van Reempts P, Gortner L, Milligan D, Cuttini M,
183   II,     9.  3.  3    |           Pereire ME, da Cunha Teles L (2004): HIV/AIDS risk perception,
184   II,     9.  3.  3    |            Silva MO, Astin M, Wyness L, Bloemenkamp KWM, Jahn A,
185   II,     9.  3.  3    |            McGarrigle CA, Østergaard L (2004): A comparison of
186   II,     9.  3.  3    |           Kirby D, Laris BA, Rolleri L (2006): Impact of sex and
187   II,     9.  3.  3    |             305~Serbanescu F, Morris L, Marin M (2001): Reproductive
188   II,     9.  5.  6    |              February 7 2002~ ~Doyal L A (1998): Draft Framework
189   II,     9.  5.  6    |              March 2005~ ~Wang S, An L, Cochran SD (2002): Women.
190  III,    10.  1.  3    |              52-62.~Green LW, Potvin L (2004): Determinants of
191  III,    10.  1.  3    |          Candeias V, Keller I, Riley L, Roy C, Tukuitonga C (2006):
192  III,    10.  1.  3    |             Health 15(1):57-62.~Sher L (2006): Alcoholism and suicidal
193  III,    10.  1.  3    |          Publishers; p. 205-8.~Tappy L, Binnert C, Schneiter Ph (
194  III,    10.  2.  1    |         Kunze M, McNeill A, Ramström L (2003): European Union policy
195  III,    10.  2.  1    |               Burns HJG, Christensen L, Denis L, Dicato M, Diehl
196  III,    10.  2.  1    |            HJG, Christensen L, Denis L, Dicato M, Diehl L, Doll
197  III,    10.  2.  1    |             Denis L, Dicato M, Diehl L, Doll R, Franceschi S, Gillis
198  III,    10.  2.  1    |          Gillis CR, Gray N, Griciute L, Hackshaw A, Kasler M, Kogevinas
199  III,    10.  2.  1    |            JJM, Crialesi R, Grötvedt L (2000): Educational differences
200  III,    10.  2.  1    |          2006; 27:517-524~ ~Joossens L, Raw M (2008): Progress
201  III,    10.  2.  1    |            who had BACs between 0.2g/l and 0.49g/l had at least
202  III,    10.  2.  1    |             between 0.2g/l and 0.49g/l had at least a three times
203  III,    10.  2.  1    |              with a BAC between 0.5g/L and 0.79g/L and 11 times
204  III,    10.  2.  1    |             between 0.5g/L and 0.79g/L and 11 times with a BAC
205  III,    10.  2.  1    |              with a BAC between 0.8g/l and 0.99 g/L.~There is a
206  III,    10.  2.  1    |            between 0.8g/l and 0.99 g/L.~There is a relationship
207  III,    10.  2.  1    |          i.e. as low as zero or 0.2g/l in a number of countries
208  III,    10.  2.  1    |         number of countries and 0.5g/l or lower in most countries
209  III,    10.  2.  1    |              JW, Gruenewald PJ, Hill L, Holder HD, Homel R, Österberg
210  III,    10.  2.  1    |             02 and C-429/02.~ ~Jones L, James M, Jefferson T, Lushey
211  III,    10.  2.  1    |             CE, Van Loveren C, Seppa L, Cochran JA, Polido M, Athanossouli
212  III,    10.  2.  1    |   Unpublished document.~ ~Koivusilta L, Honkala S, Honkala E, Rimpelä
213  III,    10.  2.  1    |        Loveren C, Fernandes B, Seppa L, Athanassouli T. Fluoride
214  III,    10.  2.  1    |             133.~ ~Maxwell K, Tucker L (1992): Effects of weight
215  III,    10.  2.  1    |               Helakorpi et al, 2007; lInstitut Roche de l’Obésité,
216  III,    10.  2.  1    |            2007; l’Institut Roche de lObésité, 2006; Institute
217  III,    10.  2.  1    |          dietary record~7~Volatier J.L. Enquête INCA Individuelle
218  III,    10.  2.  1    |          findings. Steingrímsdóttir, L, Þorgeirsdóttir H, Ólafsdóttir
219  III,    10.  2.  1    |             24-hour recall~1~Szponar L., Sekula W., Nelson M.,
220  III,    10.  2.  1(24)|      Helakorpi et al, 2007), France (lInstitut Roche de l’Obésité,
221  III,    10.  2.  1(24)|          France (l’Institut Roche de lObésité, 2006), Germany (
222  III,    10.  2.  1    |               2006), France (36.3%) (lInstitut Roche de l’Obésité,
223  III,    10.  2.  1    |             3%) (l’Institut Roche de lObésité, 2006) and Denmark (
224  III,    10.  2.  1    |              concentrations (<5.9 µg/l) in more than half (56%)
225  III,    10.  2.  1    |          with very low levels (<3 µg/l) in 20%. The ENHR confirmed
226  III,    10.  2.  1    |     Aranceta-Bartrina J, Serra-Majem L, Foz-Sala M, Moreno-Esteban
227  III,    10.  2.  1    |       Bayingana K, Demarest S, Gisle L, Hesse E, Miermans PJ, Tafforeau
228  III,    10.  2.  1    |              School Medicine (2004): L’excès de poid chez les adolescents
229  III,    10.  2.  1    |         Vieira J, Carreira M, Medina L, Reis L, Galvão-Teles A (
230  III,    10.  2.  1    |           Carreira M, Medina L, Reis L, Galvão-Teles A (2006):
231  III,    10.  2.  1    |         Davidsen M, Hesse U, Eriksen L, Christensen AL, Grønbæk
232  III,    10.  2.  1    |              C, Tudor-Smith C, Moore L (2005): Validity of self-reported
233  III,    10.  2.  1    |         relevance):~Official Journal L 052 , 22/02/2001 P. 0019 –
234  III,    10.  2.  1    |         relevance):~Official Journal L 083 , 22/03/2006 P. 0014 –
235  III,    10.  2.  1    |      LexUriServ/LexUriServ.do?uri=OJ:L:2006:083:0014:01:EN:HTML]~ ~
236  III,    10.  2.  1    |         foodstuffs. Official Journal L 109 , 06/05/2000 P. 0029 –
237  III,    10.  2.  1    |         relevance):~Official Journal L 183 , 12/07/2002 P. 0051 –
238  III,    10.  2.  1    |              foods. Official Journal L 404 , 30/12/2006 P. 0009 –
239  III,    10.  2.  1    |      LexUriServ/LexUriServ.do?uri=OJ:L:2006:404:0009:01:EN:HTML]~
240  III,    10.  2.  1    |              foods.~Official Journal L 404 , 30/12/2006 P. 0026 –
241  III,    10.  2.  1    |      LexUriServ/LexUriServ.do?uri=OJ:L:2006:404:0026:01:EN:HTML].~
242  III,    10.  2.  1    |      LexUriServ/LexUriServ.do?uri=OJ:L:2007:273:0001:0030:EN:PDF]~ ~
243  III,    10.  2.  1    |            Kriaučionienė V, Paalanen L, Prättälä R (2007): Suaugusių
244  III,    10.  2.  1    |       accessed on 8 October 2007).~ ~l'Institut Roche de l'Obésité (
245  III,    10.  2.  1    |                  l'Institut Roche de l'Obésité (2006): ObEpi-Roche
246  III,    10.  2.  1    |        épidémiologique nationale sur l'obésité et le surpoids en
247  III,    10.  2.  1    |             communication):]. Paris, l'Institut Roche de l'Obésité (
248  III,    10.  2.  1    |           Paris, l'Institut Roche de l'Obésité (in French).~ ~Institute
249  III,    10.  2.  1    |              Kaklamanou M, Loannidis L, Lanaras L, Kaklamanos L (
250  III,    10.  2.  1    |              M, Loannidis L, Lanaras L, Kaklamanos L (2004): First
251  III,    10.  2.  1    |             L, Lanaras L, Kaklamanos L (2004): First national epidemiological
252  III,    10.  2.  1    |             S, Kaklamanou M, Lanaras L, Kaklamanos I (2006): First
253  III,    10.  2.  1    |              542.~ ~Lobstein T, Baur L, Uauy R, for the IASO International
254  III,    10.  2.  1    |       Martínez-Hernández A, Enríquez L, Moreno-Moreno MJ, Martí
255  III,    10.  2.  1    |              S, Helasoja V, Paalanen L, Prättälä R (2005): Latvijas
256  III,    10.  2.  1    |              2008).~ ~Rodler I, Bíró L, Greiner F, Zajkás G, Szórád
257  III,    10.  2.  1    |             1259-1265.~ ~Serra Majem L, Ribas Barba L, Aranceta
258  III,    10.  2.  1    |           Serra Majem L, Ribas Barba L, Aranceta Bartrina J, Pérez
259  III,    10.  2.  1    |             Santana P, Peña Quintana L (2003): Obesidad infantil
260  III,    10.  2.  1    |    Gynecology 104:720726.~ ~Szponar L, Rychlik E, Oltarzewski
261  III,    10.  2.  1    |          survey]. (Edited by Szponar L, Sekula W, Rychlik E, Oltarzewski
262  III,    10.  2.  1    |          Aviles M, Shetty P, Daniels L (1998): Effectiveness of
263  III,    10.  2.  1    |             Press.~ ~Zaletel-Kragelj L, Eržen I, Fras Z (2004):
264  III,    10.  2.  1    |            1259-1271.~ ~Keinan-Boker L, Peeters PH, Mulligan AA,
265  III,    10.  2.  1    |       Linseisen J, Bergstrom E, Gafa L, Gonzalez CA, Thiebaut A,
266  III,    10.  2.  1    |               Morote Gomez P, Janzon L, Stattin P, Welch AA, Spencer
267  III,    10.  2.  1    |               Mattisson I, Weinehall L, Riboli E, Slimani N (2002):
268  III,    10.  2.  1    |      Rodriguez M, Lasheras C, Janzon L, Jansson J, Luben R, Spencer
269  III,    10.  2.  2    |       cholesterol less than 3-4 mmol/l (~ 115-155 mg/dl).~ ~Various
270  III,    10.  2.  2    |              healthy is below 5 mmol/l (~ 190 mg/dl). High Density
271  III,    10.  2.  2    |               HDL less than 1.2 mmol/l (~ 40-45 mg/dl) is considered
272  III,    10.  2.  4    |             A., Gesteland R, Walters L (1998): New Goals for the
273  III,    10.  2.  4    |                 Kononen J, Bubendorf L, Kallioniemi A, Barlund
274  III,    10.  2.  5    |          2005;353:1802-909.~ ~Bastra L, Hadders-Algra M, Neeleman
275  III,    10.  3.  1    |        Hakama M, Heid I, Kreienbrock L, Kreuzer M, Lagarde F, Mäkeläinen
276  III,    10.  3.  1    |       Rosario A, Tirmarche M, Tomáek L, Whitley E, Wichmann HE,
277  III,    10.  3.  1    |              Egan Km, Titus-Ernstoff L, Anderson Ha, Trentham-Dietz
278  III,    10.  3.  2    |          average between 1 and 11 ng/l for Pt with high peaks up
279  III,    10.  3.  2    |          with high peaks up to 44 ng/l in most sampling stations
280  III,    10.  3.  2    |              199-208.~ ~Ravindra, K, L Bencs, R van Grieken (2004):
281  III,    10.  4.  2(28)|             Directive 79/700/EEC (OJ L 187, 16.7.2002, p 30)~
282  III,    10.  4.  2(29)|              Directive 92/117/EEC(OJ L 325,12.12.2003 p. 31)~
283  III,    10.  4.  2(31)|                                   OJ L 224, 18.8.1990, p.19~
284  III,    10.  4.  2(33)|        diseases in the Community (OJ L 268, 3.10.1998,p.1)~
285  III,    10.  4.  2    |              concentrations of 598ng/L have been found in drinking
286  III,    10.  4.  2(35)|       residues in and on cereals (OJ L 221, 7.8.1986, p 37).~
287  III,    10.  4.  2(36)|      foodstuffs of animal origin (OJ L 221, 7.8.1986, p 43).~
288  III,    10.  4.  2(37)|             fruit and vegetables (OJ L 350,14.12.1986, p 71).~
289  III,    10.  4.  2(41)|        Journal of the European Union l 160/98~
290  III,    10.  4.  2    |             European Communities No. L 31/1, 1 February2002. Available
291  III,    10.  4.  2    |             European Communities No. L 338, 22 December 2005. Available
292  III,    10.  4.  2    |             European Communities No. L 043, 14 February 1997. Available
293  III,    10.  4.  2    |             European Communities No. L 117, 8 May 1990. Available
294  III,    10.  4.  2    |             European Communities No. L 106 , 17 April 2001. Available
295  III,    10.  4.  2    |             European Communities No. L 268/1, 18 October 2003.
296  III,    10.  4.  2    |             European Communities No. L 287/1, 5 November 2003.
297  III,    10.  4.  2    |             European Communities No. L 268/24, 18 October 2003.
298  III,    10.  4.  2    |             European Communities No. L 109, 6 May 2000. Available
299  III,    10.  4.  2    |             European Communities No. L 12/3, 18 January 2007 Available
300  III,    10.  4.  2    |             European Communities No. L 404/26, 30 December 2006.
301  III,    10.  4.  2    |             European Communities No. L 183/51, 12 July 2002. Available
302  III,    10.  4.  2    |             European Communities No. L 52/19, 22 February 2001.
303  III,    10.  4.  2    |             European Communities No. L 83/14, 22 March 2006.~Available
304  III,    10.  4.  2    |             European Communities No. L 165, 30 April 2004. Available
305  III,    10.  4.  2    |             European Communities No. L 395, 30 December 1989.~ ~
306  III,    10.  4.  2    |             European Communities No. L 24, 30 January 1998, 31-
307  III,    10.  4.  2    |             European Communities No. L 139, 30 April 2004.~ ~European
308  III,    10.  4.  2    |             European Communities No. L 139, 30 April 2004.~ ~European
309  III,    10.  4.  2    |             European Communities No. L 332, 30 December 1995.~ ~
310  III,    10.  4.  2    |         vegetables. Official Journal L 350 , 14/12/1990. Available
311  III,    10.  4.  3    |       maximum concentration of 10 μg/l for As in drinking water .
312  III,    10.  4.  3    |        Vahter et al, 2006). At 50 μg/l the risk 1/100 which is
313  III,    10.  4.  3    |            water are exceeding 10 μg/l and occasionally reach 25
314  III,    10.  4.  3    |             occasionally reach 25 μg/l.~ ~Access to safe drinking-water~ ~
315  III,    10.  4.  3    |           drinking water, i.e. 10 μg/l (10 ppb).~ ~The Drinking
316  III,    10.  5.  1    |          European Communities, 1998, L 330(41):32 Available at:
317  III,    10.  5.  1    |           LexUriServ/site/en/oj/1998/l_330/l_33019981205en00320054.
318  III,    10.  5.  1    |     LexUriServ/site/en/oj/1998/l_330/l_33019981205en00320054.pdf,
319  III,    10.  5.  1    |       Biology.~Konlaan, B B. Bygren, L O. Johansson, S E. Visiting
320  III,    10.  5.  1    |              Z, Sebastian A, Larsson L, Wang Z, Zhang Z, Norbäck
321  III,    10.  5.  1    |            Santé pour les Régions de l'Europe~LHHAP~Local Housing
322  III,    10.  6.  2    |             6. References~ ~Berkman, L. & Glass, T. (2000). Social
323  III,    10.  6.  2    |              support, and health. In L.Berkman & I. Kawachi (Eds.),
324   IV,    11.  6.  5    |                 Castoro C, Bertinato L et al. (2007): Day surgery:
325   IV,    11.  6.  5    |               Sons, Ltd.~ ~Gundersen L (2000): "The Effect of Clinical
326   IV,    11.  6.  5    |         Press.~ ~Lesar TS, Briceland L et al. (1997): "Factors
327   IV,    11.  6.  5    |              Europe: 53.~ ~Siciliani L, Hurst J (2004): Explaining
328   IV,    11.  6.  5    |           145-50.~ ~Starfield B, Shi L et al. (2005): "The Effects
329   IV,    11.  6.  5    |          Lancet 369: 698-700~ ~Vagac L, Haulikova L (2003): Study
330   IV,    11.  6.  5    |             700~ ~Vagac L, Haulikova L (2003): Study on the Social
331   IV,    11.  6.  5    |      Assessment 1(Doc09).~ ~Kane, R. L. (1997). Understanding Health
332   IV,    12.  2        |            is as low as zero or 0.2g/l in a number of countries,
333   IV,    12.  2        |        number of countries, and 0.5g/l or lower in most countries
334   IV,    13.  9        |                      Rigby M, Köhler L (editors) (2002): Child